|
|
|
|
|
STATE-OF-THE-INDUSTRY VIDEOS BY LEADING EXPERTS
|
|
|
|
|
|
|
Prostate Cancer Awareness in the Time of COVID
|
|
Alicia Morgans, MD, MPH
|
| In this letter from the editor, Alicia Morgans shares several reasons why it is increasingly important to spread the awareness of prostate cancer and the importance of getting screened for this disease especially during COVID-19. |
|
|
|
|
|
|
|
|
| Genetically Informed Treatment for Advanced and Metastatic Prostate Cancer
|
| Alicia Morgans, MD, MPH
|
| Alicia Morgans shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. She stresses the importance of germline testing for all patients with metastatic prostate cancer and encourages clinicians to incorporate genetic testing and post-testing counseling into their practice.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation of Germline Testing for Prostate Cancer
|
|
Veda Giri, MD
|
| In this discussion with Charles Ryan, Veda Giri highlights “Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium (PCCTC). |
|
|
|
|
|
|
|
|
|
|
|
|
The Delivering of Genetic Counseling, Processes and Outcomes, The ProGen Study
|
|
Mary-Ellen Taplin, MD
|
| Mary-Ellen Taplin joins Alicia Morgans to speak about the ProGen study. This trial measures the prevalence of germline mutations in men with prostate cancer and addresses a need to scan more patients in a more efficient way, helping to understand who should be tested and the incidence of positive results.
|
|
|
|
|
|
|
|
|
|
|
|
|
The Prevalence and Impact of Germline Mutations, PROREPAIR-B Trial
|
Elena Castro, MD
Elena Castro joins Alicia Morgans at the 2019 Prostate Cancer Foundation Retreat to discuss PROREPAIR-B, an academic prospective observational study evaluating the prevalence and impact of germline mutations in BRCA1, BRCA2, ATM and PALB2 on mCRPC outcomes.
|
|
|
|
|
|
|
|
|
|
|
|
Integrating Genomics and Genetics into Clinical Care for Prostate Cancer, A Pathologist's Perspective
|
Colin Pritchard, MD, Ph.D.
In the era that genomics and genetics are really making an impact to clinical practice, Alicia Morgans and Colin Pritchard discuss the positive results of the PROfound study.
|
|
|
|
|
|
|
|
|
|
|
|
Genetic Counseling in Prostate Cancer
|
Brittany Szymaniak, Ph.D., CGC
Alicia Morgans and Brittany Szymaniak discuss genetic counseling in GU cancers, including the challenges, the benefits, the concerns of genetic testing, and how this is accomplished in clinical practice for people with genital urinary malignancies.
|
|
|
|
|
|
|
|
|
|
|
|
Integrating PARP inhibitors into the Standard of Care for Prostate Cancer
|
Joaquin Mateo, MD, Ph.D.
Joaquin Mateo joins Charles Ryan to discuss how PARP inhibitors are being integrated into the standard of care for prostate cancer, pivotal studies that are reporting and ongoing with PARP inhibitors, and important aspect of those studies that clinicians should integrate into his or her clinical daily life.
|
|
|
|
|
|
|
|
|
|
|
|
Integrating Genetics and Genomics into Treatment Decisions for Men with Prostate Cancer
|
Panagiotis Vlachostergios, MD, Ph.D.
Panagiotis Vlachostergios joins Alicia Morgans to discuss germline and somatic genetic testing and the ways in which genomic material can be integrated into clinical practice.
|
|
|
|
|
|
|
|
|
|
